physalin F

has immunosuppressive activity; from Physalis angulata L; structure given in first source

Also Known As:

5,6-epxoyphysalin B; 5beta,6beta-epoxyphysalin B; 16,24-Cyclo-13,14-secoergost-2-ene-18,26-dioic acid, 5,6:14,17:14,27-triepoxy-13,20,22-trihydroxy-1,15-dioxo-, gamma-lactone delta-lactone, (5beta,6beta,14alpha,16beta,22alpha,25S)-

Networked: 10 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
    - Secosteroids: 22
      - physalin F: 10

Experts

1.	Soares, Milena B P: 3 articles (04/2016 - 07/2009)
2.	Ribeiro, Ivone M: 2 articles (04/2016 - 07/2009)
3.	Tomassini, Therezinha C B: 2 articles (04/2016 - 08/2010)
4.	Bellampalli, Shreya Sai: 1 article (01/2019)
5.	Cai, Song: 1 article (01/2019)
6.	Gunatilaka, A A Leslie: 1 article (01/2019)
7.	Khanna, Rajesh: 1 article (01/2019)
8.	Luo, Shizhen: 1 article (01/2019)
9.	Moutal, Aubin: 1 article (01/2019)
10.	Patek, Marcel: 1 article (01/2019)

Related Diseases

1.	Neoplasms (Cancer) 10/28/2013 - "Physalin F (a secosteroid derivative), is well recognized as a potent anticancer compound from Physalis minima L., a plant that is traditionally used to treat cancer. " 01/01/2012 - "Thus, physalin F appears to be a promising anti-cancer agent worthy of further clinical development." 05/01/1992 - "Systematic fractionation of the ethanolic extract of the plant led to characterization of physalin F from the fraction PAIV-2 as an active ingredient which showed cytotoxicity in vitro by DEA and MTT assays on 8 cancer cell lines, five human cancer cell lines: HA22T(hepatoma), HeLa(cervix uteri), KB(nasopharynx), Colo-205(colon) and Calu-1(lung); and three animal cancer cell lines: H1477(melanoma), Hep-2(laryngeal) and 8401(glioma). "
2.	Lymphoid Leukemia 05/01/1992 - "Physalin F also had an antitumor effect in vivo against P388 lymphocytic leukemia in mice whereas physalin D was inactive both in vitro and in vivo." 07/01/1992 - "Physalin F showed a stronger activity against these leukemia cells than physalin B, especially against acute myeloid leukemia (KG-1) and acute B lymphoid leukemia (B cell). " 07/01/1992 - "Both physalin B and physalin F inhibited the growth of several human leukemia cells: K562 (erythroleukemia), APM1840 (acute T lymphoid leukemia), HL-60 (acute promyelocytic leukemia), KG-1 (acute myeloid leukemia), CTV1 (acute monocytic leukemia) and B cell (acute B lymphoid leukemia). "
3.	Cutaneous Leishmaniasis 07/01/2009 - "Our results demonstrate the potent antileishmanial activity of physalins, especially physalin F, and suggest these molecules as the basis for the development of new therapeutic options for cutaneous leishmaniasis."
4.	Acute Promyelocytic Leukemia 07/01/1992 - "Both physalin B and physalin F inhibited the growth of several human leukemia cells: K562 (erythroleukemia), APM1840 (acute T lymphoid leukemia), HL-60 (acute promyelocytic leukemia), KG-1 (acute myeloid leukemia), CTV1 (acute monocytic leukemia) and B cell (acute B lymphoid leukemia). "
5.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/01/1992 - "Physalin F showed a stronger activity against these leukemia cells than physalin B, especially against acute myeloid leukemia (KG-1) and acute B lymphoid leukemia (B cell). " 07/01/1992 - "Both physalin B and physalin F inhibited the growth of several human leukemia cells: K562 (erythroleukemia), APM1840 (acute T lymphoid leukemia), HL-60 (acute promyelocytic leukemia), KG-1 (acute myeloid leukemia), CTV1 (acute monocytic leukemia) and B cell (acute B lymphoid leukemia). "

Related Drugs and Biologics

1.	Steroids
2.	Catenins
3.	GTP-Binding Proteins (G-Protein)
4.	Reactive Oxygen Species (Oxygen Radicals)
5.	Paclitaxel (Taxol)
6.	NF-kappa B (NF-kB)
7.	Cytokines
8.	Potassium Channels (Potassium Channel)
9.	Calcium Channels (Calcium Channel)
10.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

Related Therapies and Procedures

1.	Ligation